Physician profile
Ryan D Visbeen
NPI 1376179283
$3,478.44
in general payments reported to CMS, 2019-2025
20 companies · $981 in 2025
The $981 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $344 · 2022: $532 · 2023: $634 · 2024: $987 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,557 · Education: $45.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,557.25 |
| Education | $45.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $505.05 | 2021-2025 | Tavneos, Parsabiv, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $449.91 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $352.94 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $332.29 | 2024-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $291.74 | 2023-2025 | |
| Vifor Pharma, INC. | $271.52 | 2021-2024 | Veltassa, Korsuva |
| Travere Therapeutics, INC. | $246.42 | 2024-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $201.21 | 2022-2024 | Lupkynis |
| Novo Nordisk INC | $150.34 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $119.84 | 2023 | |
| Daiichi Sankyo INC. | $108.71 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $91.77 | 2021-2023 | Acthar |
| Janssen Biotech, INC. | $76.30 | 2025 | Talvey |
| Otsuka America Pharmaceutical, INC. | $70.00 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $56.16 | 2023-2025 | Tarpeyo |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $47.70 | 2023-2025 | Rayaldee |
| Lilly USA, LLC | $37.11 | 2024-2025 | Mounjaro, Zepbound |
| Renalytix Ai, INC. | $36.30 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Akebia Therapeutics INC | $18.80 | 2025 | Vafseo |
| Glaxosmithkline, LLC. | $14.33 | 2023 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Visbeen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.